Whitepaper: CMC for Fab and Fc-fusion development programmes

Antibody binding to the fusion protein of the respiratory syncytial virus

A new whitepaper is now available from Lonza Biologics entitled ‘A comprehensive and flexible approach to CMC for Fab and Fc-fusion development programs’.

Read the whitepaper to:

  • Gain insights into the diverse and complex structures of new molecular formats, often encompassing multiple chains and multiple domains
  • Understand the unique challenges faced during the process development and manufacture of these advanced proteins
  • Explore how characterising these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat

Download for free now.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free